黑料不打烊

Global Veterinary Eye Care Market Trends and Insights

Growing Pet Ownership & Spend on Advanced Veterinary Care

United States households kept 87.3 million dogs and 76.3 million cats in 2025, and the average annual spend per dog and per cat reached USD 598 and USD 529, respectively^{[1]American Veterinary Medical Association, 鈥淧et Ownership Statistics,鈥� avma.org}. Routine wellness traffic fell, yet ophthalmology referrals rose, revealing a shift toward interventions that deliver a visible quality-of-life lift. Surveyed owners cite affordability and appointment scarcity as primary barriers, yet 37% still prioritize eye surgery when vision loss threatens activity levels. Millennials and Generation Z over-index on specialty procedures because they view pets as family. Although total veterinary expenditures dipped 4% between 2023 and 2024, clinics that prove rapid clinical gains continue to defend premium fees.

Rising Prevalence of Ocular Disorders in Companion Animals

A multi-year study covering 2021-2024 found ocular disease in 2.77% of dogs, led by cataracts, corneal ulcers, and conjunctivitis. Breed selection amplifies risk as French Bulldogs and Pinschers share narrow gene pools that magnify hereditary problems. The ACVO Blue Book now tracks more than 200 breed-linked eye defects, helping breeders test early, yet commercial incentives still favor popular brachycephalic lines. Equine recurrent uveitis affects up to 25% of horses in some regions, creating new demand for long-acting implants. Wider use of genetic screens uncovers subclinical lesions sooner, so the addressable population keeps rising.

Expanding Portfolio of Topical Ophthalmic Drugs & Ointments

The FDA lists cyclosporine 0.2% ointment, triple-antibiotic gels, and gentamicin drops under 21 CFR Part 524. Dechra added Remend Corneal Repair Gel in 2024, and early field data show faster epithelialization than standard therapy. Tarsus is repurposing Lotilaner 0.25% solution for canine blepharitis after its human approval. New sterility guidance issued in 2024 is driving manufacturers to upgrade their filling lines, delaying smaller entrants but ensuring product safety. As formularies widen, clinics gain drug choices that match disease stage and owner budget.

Demand for Minimally Invasive Ophthalmic Surgeries

Phacoemulsification restores vision in more than 90% of canine cataract cases when performed by specialists. Laser cyclophotocoagulation and shunt implantation now treat glaucoma without enucleation, preserving appearance and comfort. Equipment costs exceeding USD 50,000 continue to limit adoption in rural clinics. To close gaps, vendors bundle lasers with remote mentoring so general practitioners can start with lower case volumes. Insurers cover most of the cost, yet uninsured animals still risk blindness, so tiered pricing and leasing are under trial.

High Cost of Advanced Ocular Equipment & Surgery

Phaco units, OCT scanners, and diode lasers each exceed USD 50,000, which sidelines many single-doctor practices. Average canine cataract claims reached USD 5,785.40 between 2019-2024, with owners still paying USD 1,428.60 after insurance. Clinics in Latin America and India struggle with import duties and currency fluctuations that further inflate prices. Subscription leasing is being tested, yet low case volumes in rural markets complicate break-even projections. Consequently, uninsured animals often lose eyes to budget-friendly enucleation, holding back global procedure counts.

Limited Insurance Reimbursement for Veterinary Eye Care

Trupanion covers hereditary eye disease but imposes waiting periods, while Embrace aggregates bilateral conditions and caps payouts. United Kingdom policies classify time-limited and lifetime coverage differently, confusing owners about eligibility for long-term therapies. In the Asia-Pacific region, insurance penetration sits in the single digits, so elective surgeries remain out of reach for most. Misaligned definitions fuel distrust and delay care until vision loss becomes irreversible.

*Our updated forecasts treat driver/restraint impacts as directional, not additive. The revised impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Products & Services: Services Grow as Tele-Ophthalmology Scales

Services generated rapid momentum, increasing at a 6.85% CAGR for 2026-2031, while products preserved a 75.55% revenue lead in 2025. Clinics increasingly unbundle diagnostics, surgery, and follow-up care from product sales, creating recurring service revenue. Tele-ophthalmology sessions let general practitioners triage conjunctivitis or dry eye before escalating complex ulcers. Even though no AI platform meets validation standards today, remote guidance already reduces referral wait times. The trajectory suggests that the Veterinary Eye Care market will continue to shift toward bundled procedure-plus-monitoring packages.

Drugs remain the backbone of revenue, anchored by cyclosporine ointment and triple-antibiotic gels registered under 21 CFR Part 524. Dechra鈥檚 2024 regenerative gel added a premium tier that accelerates corneal recovery and lowers surgery rates. Instruments and implants remain niche but command high prices due to precision engineering. Diagnostic devices such as rebound tonometers now occupy reception desks in mainstream clinics, narrowing the referral funnel and lifting procedure capture rates inside primary practices.

By Animal Type: Equine Uveitis Drives Premium Pricing

Dogs accounted for 50.53% of 2025 revenue, reflecting both population dominance and a genetic predisposition to cataracts and KCS. Yet the fastest growth lies in equine cases, where suprachoroidal cyclosporine implants fetch above USD 2,000 per eye. Owners of performance horses accept these costs to preserve their sport careers. Cats add volume with viral conjunctivitis and corneal sequestrum, but lower price points limit category value. Niche exotic rabbits and birds grow slowly as urban clinics add small-mammal service lines.

Dogs will retain mass-market importance, yet horses add disproportionate dollars per procedure. As stem-cell research matures, premium therapies may first migrate to equine referrals, then trickle into canine practice. Clinics that build mixed-animal expertise gain a hedge against demand swings inside any single species pool.

By Application: Corneal Ulcers Benefit From Regenerative Innovation

Keratoconjunctivitis sicca still topped with 32.15% share in 2025, thanks to chronic drug therapy. However, corneal ulcers post the fastest 7.82% CAGR because regenerative crosslinking, amniotic grafts, and platelet-rich plasma shorten healing. Clinics monetizing these techniques capture new revenue while reducing repeat drug visits. Glaucoma maintains clinical urgency but carries a poorer prognosis, so enucleation persists where laser shunts are unavailable.

Corneal innovations showcase how research can move from human protocols to pets within 5 years. As clinical evidence solidifies, reimbursement support may broaden, driving even stronger expansion. Clinics that master crosslinking now will set local standards before competitors catch up.

By End-User: Clinics Democratize Access Through Equipment Adoption

Veterinary hospitals accounted for 62.52% of 2025 sales because they own phaco machines and OCT systems, yet general clinics grew 6.12% annually as they bought rebound tonometers and fundus cameras. This democratization reduces wait times and captures moderate cases locally. Academic centers host the most advanced imaging, but their market share remains minor. Tele-ophthalmology gives small clinics instant specialist input, improving case triage and owner confidence.

As the Veterinary Eye Care market size expands, hospitals will keep complex surgery volume, yet clinics will own the routine ulcer, KCS, and early glaucoma pipeline. Equipment vendors who offer leasing and online training stand to win first-time buyers in suburban practices.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America retained 38.62% of 2025 global revenue, driven by dense specialty networks and 25%-plus pet insurance penetration. Average U.S. spend per dog touched USD 598 while overall vet spending slipped 4% as owners skipped routine checks but not sight-saving surgery. FDA sterility rules rolled out in 2024 give U.S. drug standards outsized global influence. Canada and Mexico expand steadily, though rural shortages of specialists mirror those in the U.S. farm belt.

Asia-Pacific records the quickest 6.22% CAGR through 2031. China鈥檚 urban singles and seniors drive companion adoption, yet care remains city-centric. Japan鈥檚 aging society values pet companionship, channeling spending into advanced surgery. Australia benefits from high insurance uptake and seamless EU-aligned regulation for imported devices. India and South Korea attract private equity to build multi-location chains that embed ophthalmology suites. Board-certified ophthalmologists remain rare, so simplified lasers and remote mentoring gain traction.

Europe offers mature demand, with Germany, the United Kingdom, and France leading specialty density. The EMA streamlines cross-border approvals, yet Eastern Europe faces staffing gaps. The United Kingdom鈥檚 mix of lifetime and time-limited insurance plans affects reimbursement consistency. In the Middle East and Africa, only the United Arab Emirates and South Africa host sizeable referral centers, while Latin America鈥檚 Brazil and Argentina grow but wrestle with currency and import duty volatility.